Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Carboplatin in combination with Paclitaxel, Pertuzumab, and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Perjeta (pertuzumab) [product monograph]. HC. Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
Phesgo (pertuzumab and trastuzumab) [product monograph]. HC. Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.